E-MAIL UPDATES

Click here to join
our Electronic Communications.

Listen to our upcoming & hosted webcast by Immutep “KOL Call on Novel IO Therapy (eftilagimod alpha)” Wednesday, Jun 26, 2019, 11:00 AM EDT

 

Investors & Media

Whats new.

Press releases

Press releases.

Immutep Completes Patient Enrolment of the AIPAC Phase IIb Clinical Trial in Metastatic Breast Cancer

June 25th 2019
press releases

Immutep Announces Australian Patent Granted for Eftilagimod Alpha in Chemo-Immunotherapy

June 21st 2019
press releases

Immutep Completes Recruitment of Initial Cohort in 1st Line NSCLC Patients for TACTI-002 Trial

June 13th 2019
press releases
more

Investor updates

Investor updates.

Investor Update - January 2019

January 31st 2019
investor updates

Investor Update - June 2018

June 19th 2018
investor updates

Investor Update - December 2017

December 21st 2017
investor updates
more

Analyst reports

Analyst reports.

Maxim - Immutep Provides Corporate Update, Data Points Ahead in 2019

April 30th 2019
analyst reports

goetzpartners securities - Unlocking the value of LAG-3 in autoimmunity

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

April 23rd 2019
analyst reports

Edison - Encouraging results for efti and IMP761

April 8th 2019
analyst reports
more